Fig. 4

Comparison of the mean change in M2BPGi at 240 weeks after the start of the trial. M2BPGi levels were 0.091 ± 0.035 and 0.117 ± 0.036 in the ETV continuation and TAF change groups, respectively, showing no significant difference (p = 0.610). ETV entecavir, TAF tenofovir alafenamide, M2BPGi Mac-2 binding protein glycosylation isomer.